Policy & Economic Analysis

Members of the Center conduct empiric economic analyses including evaluation and cost-effectiveness analyses of specific cancer treatments and discrete choice experiments. Additionally, members utilize decision modeling to support policy analyses and develop payment mechanism models (e.g. outcomes-based contracting).

Learn more about value frameworks from faculty member Andrew Briggs.

Bach PB. New Math on Drug Cost-Effectiveness. N Engl J Med. 2015 Nov 5;373(19):1797-9. doi: 10.1056/NEJMp1512750.

Bach PB, Giralt SA, Saltz LB. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. JAMA. 2017 Nov 21;318(19):1861-1862. doi: 10.1001/jama.2017.15218.

Bach PB, Kaltenboeck A.“Outcomes-Based Drug Contracts Do Not Move Us Closer to Value.” Morning Consult. June 21 2017.

Parker C, Woods B, Eaton J, Ma E, Selby R, Benson E, Engstrom A, Sajosi P, Briggs A, Bonthapally V. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. J Med Econ. 2017 Jan;20(1):8-18. Epub 2016 Aug 11.